[go: up one dir, main page]

ATE545651T1 - Vektoren zur expression von hml-2-polypeptiden - Google Patents

Vektoren zur expression von hml-2-polypeptiden

Info

Publication number
ATE545651T1
ATE545651T1 AT03741966T AT03741966T ATE545651T1 AT E545651 T1 ATE545651 T1 AT E545651T1 AT 03741966 T AT03741966 T AT 03741966T AT 03741966 T AT03741966 T AT 03741966T AT E545651 T1 ATE545651 T1 AT E545651T1
Authority
AT
Austria
Prior art keywords
hml
promoter
polypeptides
nucleic acid
sequence encoding
Prior art date
Application number
AT03741966T
Other languages
English (en)
Inventor
Stephen Hardy
John Donnelly
Megede Jan Zur
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Priority claimed from PCT/US2003/018666 external-priority patent/WO2003106634A2/en
Application granted granted Critical
Publication of ATE545651T1 publication Critical patent/ATE545651T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03741966T 2002-06-13 2003-06-13 Vektoren zur expression von hml-2-polypeptiden ATE545651T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38883102P 2002-06-13 2002-06-13
US47218903P 2003-05-20 2003-05-20
PCT/US2003/018666 WO2003106634A2 (en) 2002-06-13 2003-06-13 Vectors for expression of hml-2 polypeptides

Publications (1)

Publication Number Publication Date
ATE545651T1 true ATE545651T1 (de) 2012-03-15

Family

ID=34221115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741966T ATE545651T1 (de) 2002-06-13 2003-06-13 Vektoren zur expression von hml-2-polypeptiden

Country Status (6)

Country Link
US (1) US8518694B2 (de)
EP (2) EP2302039A1 (de)
JP (3) JP2005535308A (de)
AT (1) ATE545651T1 (de)
AU (1) AU2003276679A1 (de)
CA (1) CA2489292A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535765A (ja) * 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
AU2019334676B2 (en) * 2018-09-06 2025-06-05 Centre Léon-Bérard HERV-K-derived antigens as shared tumor antigens for anti-cancer vaccine
KR20240093924A (ko) 2018-09-18 2024-06-24 브이엔브이 뉴코 인크. Arc 기반 캡시드 및 이의 용도
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1660401A (en) 1926-05-10 1928-02-28 Strauss Ets Lighter
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0487587A1 (de) 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DK0463151T3 (da) * 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
IE912662A1 (en) 1990-07-27 1992-01-29 Chiron Corp Large comb-type branched polynucleotides
JP3337214B2 (ja) 1990-12-20 2002-10-21 アーチ・ディベロップメント・コーポレーション 電離線による遺伝子発現の調節
JPH05509234A (ja) 1991-02-08 1993-12-22 ルセル　ユクラフ ヒトＴリンパ球レセプターのα鎖の可変領域をコードするヌクレオチド配列対応するペプチドセグメント並びに診断及び治療への利用
DE59108506D1 (de) 1991-04-16 1997-03-06 Siemens Ag Ausgangpufferverstärker
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5650277A (en) * 1992-07-02 1997-07-22 Diagenetics Ltd. Method of determining the presence and quantifying the number of di- and trinucleotide repeats
EP0652950B1 (de) 1992-07-24 2007-12-19 Amgen Fremont Inc. Bildung von xenogenen antikörpern
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
DE69431750T2 (de) 1993-04-22 2003-04-03 Skyepharma Inc., San Diego Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (de) 1993-09-15 1997-07-09 Viagene Inc Rekombinanter Alphavirus Vektor
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
BR9408072A (pt) 1993-11-16 1997-08-12 Depotech Corp Vesículas com liberação controlada de ativos
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) * 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
US5571639A (en) * 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5858723A (en) * 1995-12-05 1999-01-12 Behringwerke Aktiengesellschaft Polypeptides and antibodies for diagnosing and treating seminoma
AU1575697A (en) 1996-01-10 1997-08-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of cancer
AU2253397A (en) 1996-01-23 1997-08-20 Affymetrix, Inc. Nucleic acid analysis techniques
WO1997029212A1 (en) 1996-02-08 1997-08-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
ATE424463T1 (de) 1996-05-06 2009-03-15 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5916872A (en) 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (de) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Öl-in-Wasser Emulsionen mit Saponinen
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
EP1069910A1 (de) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant zusammensetzungen
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1104473A2 (de) 1998-08-10 2001-06-06 Incyte Pharmaceuticals, Inc. Proteasen und assoziierte proteine
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
AU4673099A (en) 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US6753314B1 (en) * 1999-04-01 2004-06-22 Curagen Corporation Protein-protein complexes and methods of using same
HK1044484B (en) 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
JP2003518364A (ja) 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
EP1074617A3 (de) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
HK1046861A1 (zh) 1999-09-24 2003-01-30 Smithkline Beecham Biologicals S.A. 包括聚氧乙烯烷基酯或者醚以及至少一種非離子表面活性劑的佐劑
CO5200837A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
AU2074201A (en) 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
NO314091B1 (no) 2000-01-12 2003-01-27 Biotec Pharmacon Asa Varmelabil uracil-DNA-glykosylase, DNA-sekvens som koder for enzymet, mikroorganisme som inneholder DNA-sekvensen, samt anvendelse av enzymet
AU2001241408A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001057251A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004535765A (ja) * 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
EP1578919B1 (de) * 2001-12-07 2010-02-17 Novartis Vaccines and Diagnostics, Inc. Bei prostatakrebs hochreguliertes endogenes retrovirus
EP1521594B1 (de) * 2001-12-07 2013-10-02 Novartis Vaccines and Diagnostics, Inc. Mit onkogener transformation in verbindung gebrachte endogene retroviruspolypeptide
WO2004069174A2 (en) * 2003-01-31 2004-08-19 Slil Biomedical Corporation Monitoring and treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
JP2009268478A (ja) 2009-11-19
EP1532161B1 (de) 2012-02-15
AU2003276679A1 (en) 2003-12-31
US20100086565A1 (en) 2010-04-08
EP2302039A1 (de) 2011-03-30
EP1532161A2 (de) 2005-05-25
US8518694B2 (en) 2013-08-27
JP2013143953A (ja) 2013-07-25
AU2003276679A8 (en) 2003-12-31
EP1532161A4 (de) 2006-05-24
JP2005535308A (ja) 2005-11-24
CA2489292A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
ATE421537T1 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
NO20024475D0 (no) Produksjon av rekombinante blodkoagulasjonsfaktorer i humane cellelinjer
JP2020510426A5 (de)
DE60120500D1 (de) In Knorpelgeweben stark exprimiertes Gen
ATE320484T1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
ATE420191T1 (de) Promotoren zur expression im modifizierten vacciniavirus ankara
ATE545651T1 (de) Vektoren zur expression von hml-2-polypeptiden
ATE461283T1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
MX2022011806A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
Zhang et al. RETRACTED ARTICLE: A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas
ATE408029T1 (de) Verfahren zur herstellung und identifizierung löslicher proteindomänen
Sadikoglou et al. Comparative analysis of internal ribosomal entry sites as molecular tools for bicistronic expression
DE60132271D1 (de) Verwendung von CD34 oder eines davon abgeleiteten Polypeptids als Oberflächenmarker für Gentransfer
CN112941028A (zh) 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
WO2005005612A3 (en) Tag-1 and tag-2 proteins and uses thereof
CN103114104A (zh) 一种抑癌肽基因重组及其抗肿瘤应用
WO2002101069A3 (en) Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
WO2002060928A3 (en) Medane genes and proteins
DE60310708D1 (de) In vivo stabilsierung von plasmiden
JP6830651B2 (ja) ペプチド、ポリヌクレオチド、ベクター、形質転換体、ＮＦκＢ阻害剤、及びＮＦκＢ亢進性疾患の治療剤
JP2005518198A5 (de)
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
EP1201680A3 (de) Tumorsuppressor-Polypeptide aus CHC1-L (chromosome condensation 1-like)
ATE423200T1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon